AbbVie Inc. $ABBV Shares Bought by Compound Planning Inc.

Compound Planning Inc. grew its position in AbbVie Inc. (NYSE:ABBV) by 25.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,807 shares of the company’s stock after acquiring an additional 3,853 shares during the quarter. Compound Planning Inc.’s holdings in AbbVie were worth $4,355,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Evolution Wealth Management Inc. acquired a new position in AbbVie in the second quarter valued at $26,000. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the second quarter worth about $28,000. Redmont Wealth Advisors LLC acquired a new position in AbbVie in the 3rd quarter valued at about $41,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie during the 2nd quarter valued at approximately $36,000. Finally, Delos Wealth Advisors LLC purchased a new stake in AbbVie during the 2nd quarter valued at approximately $39,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Up 1.9%

NYSE:ABBV opened at $229.19 on Tuesday. The firm’s fifty day simple moving average is $224.07 and its 200-day simple moving average is $222.45. The stock has a market cap of $405.07 billion, a PE ratio of 97.11, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the firm earned $2.16 earnings per share. The firm’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Raymond James Financial set a $256.00 target price on AbbVie in a report on Monday, November 3rd. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Evercore cut their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. Piper Sandler lifted their target price on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Finally, JPMorgan Chase & Co. increased their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $252.79.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Announced a $380 million build-out of two active pharmaceutical ingredient (API) facilities at its North Chicago campus to support next‑generation neuroscience and obesity medicines; expands domestic capacity and supports long‑term product supply and commercialization. AbbVie to Invest $380 Million in North Chicago
• Positive Sentiment: U.S. FDA approved the combination of Venclexta and acalabrutinib for previously untreated chronic lymphocytic leukemia (CLL), which could expand label use and drive additional oncology revenue. FDA approves Venclexta + acalabrutinib for CLL
• Positive Sentiment: Advanced ABBV‑8736 into a Phase 1 trial comparing injection routes (PK-focused) — early clinical progress that de‑risks part of the pipeline, though commercial impact is longer term and uncertain. AbbVie Advances ABBV-8736 With New Trial
• Positive Sentiment: Erste Group raised its FY2026 EPS forecast for AbbVie, lifting expectations for near‑term earnings which can support valuation and investor sentiment. AbbVie FY2026 EPS Forecast Boosted
• Neutral Sentiment: Industry talent movement: IDEAYA named a former AbbVie VP as Chief Development Officer — notable for personnel flow but unlikely to move AbbVie’s near‑term fundamentals. IDEAYA appoints ex‑AbbVie exec
• Negative Sentiment: Analyst commentary highlights a growth showdown with Johnson & Johnson and ongoing patent/competition risks — a reminder that AbbVie faces external pressures that could cap upside if key franchises weaken. Johnson & Johnson vs. AbbVie: A Growth Showdown

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.